Ten notable “trial flops of 2018” included five Alzheimer’s trials and five in other conditions, and the majority failed due to lack of efficacy.  The developers of these drug candidates were big pharma companies –Merck & Co., Roche, Johnson & Johnson, Celgene, Takeda Pharmaceutical, Boehringer Ingelheim – as well as smaller companies including Incyte Corporation, eTV Therapeutics, Sarepta Therapeutics, and Alkermes. (BioSpace)